The withdrawal follows a supplementary assessment of the benefit-risk profile of Ixchiq in travelers, conducted by the ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that, following a further ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Valneva says it’s working with French regulators on next steps and pointed out that the country's health authority is maintaining its recommendation for Ixchiq’s use in people ages 18 to 64. (valneva) ...

Valneva SE (NASDAQ:VALN), on Monday, sold the FDA Priority Review Voucher (PRV) for $103 million (€95 million). The company was awarded a tropical disease PRV in November 2023 following the FDA ...

A Valneva chikungunya vaccine under regulatory scrutiny for much of this year amid safety concerns is now no longer permitted for sale in the U.S. market. The FDA has suspended the biologics license ...

Valneva SE offers exposure to a robust travel vaccine portfolio that includes Ixiaro, Dukoral, and Ixchiq. Ixiaro generated roughly €94.1 million in 2024 and remains Valneva’s main revenue vertical.

The Ixchiq update comes as a new wave of chikungunya outbreaks have caught the attention of the World Health Organization. ((Pixabay)) The FDA has removed a pause in the use of Valneva’s chikungunya ...

Positive Phase 3 data from Bavarian Nordic's chikungunya virus (CHIKV) vaccine candidate, PXVX0317, reinforces bullish view on Valneva's VLA1553 due to its superior clinical profile. Valneva's VLA1553 ...

Saint-Herblain (France), October 25, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces the submission of a marketing application with the European ...